Female gender has been associated with better outcomes in schizophrenia spectrum disorders (SSDs). This study investigated gender differences in recovery-related outcomes and psychiatric rehabilitation needs in a multicenter sample of patients with SSD.
Are women with vaginismus more susceptible to developing bipolar disorder? This study investigated the affective temperaments of women with vaginismus compared to healthy controls. The results may surprise you.
Women with bipolar disorder are vulnerable to mood episodes and postpartum psychosis due to pregnancy. This report describes the management of a woman with bipolar I disorder undergoing multiple ovarian stimulation cycles to get pregnant.
Gestational exposure to antidepressants has been associated with risk of autism and ADHD, and a recent study also showed maternal depression as a risk factor. Intriguingly, paternal depression was also a risk factor. Dr Andrade explores the implications.
This study compared the prevalence of depression and suicidal behavior along with the use and cost of related treatment in young adults with and without attention-deficit/hyperactivity disorder using commercial claims data.
Postmenopausal women may be deficient in the neuroactive steroid allopregnanolone. This study examined oral ganaxolone, an allopregnanolone analog, as augmentation therapy in postmenopausal women with inadequate response to traditional antidepressants.
Distinguishing the effects of antidepressant use in pregnant women from those of the underlying maternal illness and factors such as stress and diet is difficult. This review aims to untangle effects of antidepressant exposure from other factors.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”